Rilvegostomig(Rilvegostomig) - 药物靶点：PD-1 x TIGIT_在研适应症：食管腺癌，Claudin 18.2阳性 / HER2阴性的实体瘤，CLDN18.2阳性胃食管交界处腺癌_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

AZD 2936、AZD-2936

靶点

PD-1 x TIGIT

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)、TIGIT抑制剂(T细胞免疫球蛋白ITIM结构域抑制剂)

治疗领域

肿瘤消化系统疾病呼吸系统疾病+ [3]

在研适应症

食管腺癌Claudin 18.2阳性 / HER2阴性的实体瘤CLDN18.2阳性胃食管交界处腺癌+ [40]

非在研适应症-

原研机构

AstraZeneca PLC

在研机构

AstraZeneca PLCAstraZeneca AB

Compugen Ltd.

+ [3]

非在研机构-

权益机构

AstraZeneca PLC

MedImmune LLC

Compugen Ltd.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 18899517L

来源: *****

Sequence Code 18899526H

来源: *****

Sequence Code 719888445H

来源: *****

Sequence Code 719888446L

来源: *****

关联

34

项与 Rilvegostomig 相关的临床试验

NCT07431281

/ Recruiting临床3期

A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.

开始日期2026-02-03

申办/合作机构

AstraZeneca PLC

NCT07221253

/ Recruiting临床3期

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.

开始日期2025-12-04

申办/合作机构

AstraZeneca PLC

NCT07161414

/ Recruiting临床1期

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

开始日期2025-11-25

申办/合作机构

AstraZeneca PLC

[+1]

100 项与 Rilvegostomig 相关的临床结果

登录后查看更多信息

100 项与 Rilvegostomig 相关的转化医学

登录后查看更多信息

100 项与 Rilvegostomig 相关的专利（医药）

登录后查看更多信息

5

项与 Rilvegostomig 相关的文献（医药）

2026-01-01·JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer

Article

作者: Lim, Eric ; Forcina, Alessandra ; Opitz, Isabelle ; Yanagawa, Jane ; Batig, Anastasiya ; Harpole, David ; Felip, Enriqueta ; Tsutani, Yasuhiro ; Jones, David R ; Lyfar, Pavlo ; Bodla, Shankar ; Dacic, Sanja ; Ganti, Apar Kishor ; Tan, Daniel S W

BACKGROUND:

Five-year disease recurrence rates for patients with stage I non-small cell lung cancer (NSCLC) postsurgery are variable (15%-40%). There is an urgent need for novel biomarker strategies to identify high-risk patients who may benefit from adjuvant treatment. High-risk pathologic features, including high-grade histology and lymphovascular or visceral pleural invasion, serve as independent risk factors for worse outcomes. Preoperative circulating tumor DNA (ctDNA) detection is also correlated with poorer outcomes in stage I NSCLC. Datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate composed of a humanized anti-TROP2 antibody conjugated to a potent topoisomerase I inhibitor via a plasma-stable linker, and rilvegostomig, an Fc-reduced monovalent bispecific humanized IgG1 antibody targeting both PD-1 and TIGIT receptors, have shown promise in NSCLC studies. Combining Dato-DXd with rilvegostomig may improve treatment outcomes in selected patients with stage I NSCLC.

METHODS:

TROPION-Lung12 (NCT06564844) is a phase 3 randomized study enrolling approximately 660 patients with stage I adenocarcinoma without actionable genomic alterations who have undergone complete surgical resection. Eligible patients must have preoperative ctDNA-positive status or 1 or more high-risk pathologic features. Patients will be randomized 2:1:2 to receive Dato-DXd (6 mg/kg intravenously [IV] every 3 weeks) plus rilvegostomig (750 mg IV every 3 weeks) for 4 cycles, followed by rilvegostomig (up to 12 months/18 cycles total), rilvegostomig alone (up to 12 months/18 cycles total), or standard of care (SoC) for up to 12 months. The primary endpoint is disease-free survival, assessed using blinded independent central review according to RECIST v1.1, with key secondary endpoints including overall survival, for the Dato-DXd plus rilvegostomig arm versus the SoC arm.

POSTGRADUATE MEDICAL JOURNAL

Retraction of: Volrustomig/Rilvegostomig related “triple M”—myasthenia gravis and overlap syndrome

Article

Frontiers in Oncology

Correction: TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naïve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations

[This corrects the article DOI: 10.3389/fonc.2025.1721624.].

312

项与 Rilvegostomig 相关的新闻（医药）

2026-06-08

·PRNewswire

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET. A live webcast will be accessible on the Investor Relations section of the Compugen website at . A replay will also be available following the live event. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Lindsey Trickett Email: [email protected] Tel: +1 415 373 0892 SOURCE Compugen Ltd. 21% more press release views with Request a Demo

免疫疗法临床1期引进/卖出临床2期

2026-06-08

·动脉网

Compugen将参加琼斯贸易公司举办的与人工智能/机器学习驱动药物研发领域领袖的炉边谈话系列活动Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

HOLON, Israel 以色列霍隆, ，June 8, 2026 2026年6月8日/PRNewswire/ -- /美通社/ --Compugen Ltd. Compugen有限公司(Nasdaq: （纳斯达克：CGEN CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will participate in Jones Trading's Mapping the Path from Target to Patient: Fireside Chat Series with Leaders in AI/ ML-based Drug Development on Monday, June 15, 2026, from 10:30-11:00 AM ET.. )（特拉维夫证券交易所股票代码：CGEN）是一家处于临床阶段的癌症免疫治疗公司，也是由人工智能/机器学习驱动的计算靶点发现领域的先驱，今日宣布，公司管理层将于2026年6月15日星期一上午10:30至11:00（美国东部时间）参加琼斯交易公司举办的“从靶点到患者：基于人工智能/机器学习的药物开发领导者炉边谈话系列”活动。A live webcast will be accessible on the Investor Relations section of the Compugen website at Compugen 网站投资者关系栏目将提供网络直播，网址为www.cgen.com www.cgen.com. A replay will also be available following the live event. 直播结束后也将提供回放。AboutCompugen 关于CompugenCompugenis a clinical-stage therapeutic discovery and development company utilizing Unigen Compugen 是一家利用 Unigen 平台的临床阶段治疗发现与开发公司™ 商标, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stageprograms: COM701, COM902, rilvegostomigand GS-0321 (previously COM503). ，其由人工智能/机器学习驱动的计算发现平台，用于识别新型药物靶点并开发癌症免疫治疗领域的疗法。Compugen 创新的肿瘤免疫管线包含四个处于临床阶段的项目：COM701、COM902、rilvegostomig 和 GS-0321（前身为 COM503）。COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). COM701（一种潜在的首创抗PVRIG抗体）和COM902（一种抗TIGIT抗体）已作为单药及联合疗法在实体瘤治疗中进行了评估。目前，Compugen公司正在开展一项盲法随机卵巢癌平台试验，评估COM701作为单药在复发性铂敏感卵巢癌维持治疗中的疗效（该试验名为MAIA-ovarian试验）。Rilvegostomig,aPD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developedby AstraZeneca pursuant to an exclusivelicense agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 andPhase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gileadand is being evaluated in a Phase 1 clinical trial that Compugen is conducting.In addition, Compugen's has an early-stageimmuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Rilvegostomig 是一种 PD-1/TIGIT 双特异性抗体，其 TIGIT 组分源自 COM902 项目，由阿斯利康（AstraZeneca）根据与 Compugen 签订的独家许可协议进行开发，目前正在多项 III 期、II 期和 I 期临床试验中接受评估。GS-0321（此前称为 COM503）是 Compugen 研发的潜在首创高亲和力抗体，可阻断 IL-18 结合蛋白与 IL-18 之间的相互作用，已授权给吉利德科学（Gilead），并在由 Compugen 开展的一项 I 期临床试验中接受评估。此外，Compugen 还拥有早期阶段的免疫肿瘤学产品管线，包括旨在通过多种机制增强抗癌免疫力的研究项目。Compugen's shares are listed on Nasdaq and the Tel AvivStock Exchange under the ticker symbol CGEN.. Compugen 的股票在纳斯达克和特拉维夫证券交易所上市，股票代码为 CGEN。Company contact: 公司联系人：Lindsey Trickett 林赛·特里凯特Email: 电子邮件：[emailprotected] [emailprotected]Tel: +1415 373 0892 电话：+1 415 373 0892SOURCE Compugen Ltd. 来源：Compugen 有限公司21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示

2026-06-07

·信狐药迅

34个1类创新化药/生物制品获批临床| 新获批(6.1-6.7）

每周药品注册获批数据，分门别类呈现，一目了然。(6.1-6.7）新药上市申请无新药临床申请药品名称企业注册分类受理号 ABP-671片杭州新元素药业股份有限公司 1 CXHL2600515 ABP-671片杭州新元素药业股份有限公司 1 CXHL2600514 PP011胶囊沛肽(上海)医药科技有限公司 1 CXHL2600460 TJ0113胶囊杭州天玑济世生物科技有限公司 1 CXHL2600383 RGT-490片上海齐鲁锐格医药研发有限公司 1 CXHL2600387 RGT-490片上海齐鲁锐格医药研发有限公司 1 CXHL2600386 CH3127片苏州春海生物医药有限公司 1 CXHL2600369 CH3127片苏州春海生物医药有限公司 1 CXHL2600368 CH3127片苏州春海生物医药有限公司 1 CXHL2600367 BY101921片康百达(四川)生物医药科技有限公司 1 CXHL2600379 BY101921片康百达(四川)生物医药科技有限公司 1 CXHL2600378 HP-002片上海超阳药业有限公司 1 CXHL2600354 HP-002片上海超阳药业有限公司 1 CXHL2600356 HP-002片上海超阳药业有限公司 1 CXHL2600355 重组呼吸道合胞病毒疫苗(CHO细胞) 易康生物(苏州)有限公司 1.2 CXSL2600311 重组呼吸道合胞病毒疫苗(CHO细胞)(佐剂) 易康生物(苏州)有限公司 1.2 CXSL2600309 冻干口服轮状减毒活疫苗(Vero细胞) 成都迈科康生物科技股份有限公司 2.2 CXSL2600315 新型佐剂流感病毒裂解疫苗华兰生物疫苗股份有限公司 3.2 CXSL2600319 JSKN016SC注射液江苏康宁杰瑞生物制药有限公司 1 CXSL2600458 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2600461 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2600462 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2600460 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2600459 UX-DA003注射液上海跃赛生物科技有限公司 1 CXSL2600438 ADRX-0405 上海德烽药业有限公司 1 CXSL2600358 9MW5211注射液迈威(上海)生物科技股份有限公司 1 CXSL2600352 注射用SKB571 四川科伦博泰生物医药股份有限公司 1 CXSL2600350 QLS2311注射液齐鲁制药有限公司 1 CXSL2600353 注射用BL-M08D1 成都百利多特生物药业有限责任公司 1 CXSL2600348 SHR-6914注射液苏州盛迪亚生物医药有限公司 1 CXSL2600339 SYS6063注射液石药集团中奇制药技术(石家庄)有限公司 1 CXSL2600308 仿制药申请无进口申请药品名称企业注册分类受理号 Brenipatide注射液 Eli Lilly and Company 1 JXHL2600094 Brenipatide注射液 Eli Lilly and Company 1 JXHL2600093 Brenipatide注射液 Eli Lilly and Company 1 JXHL2600092 Brenipatide注射液 Eli Lilly and Company 1 JXHL2600091 那米司特片 Boehringer Ingelheim International GmbH 2.4 JXHL2600090 那米司特片 Boehringer Ingelheim International GmbH 2.4 JXHL2600089 那米司特片 Boehringer Ingelheim International GmbH 2.4 JXHL2600088 注射用阿莫西林钠克拉维酸钾 LABORATOIRES DELBERT 5.1 JXHL2600081 ABBV-438注射用粉末 AbbVie Inc. 1 JXSL2600106 AZD2936 AstraZeneca AB 1 JXSL2600087 注射用precemtabart tocentecan Merck Healthcare KGaA 1 JXSL2600085 中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗临床申请

100 项与 Rilvegostomig 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
食管腺癌	临床3期	美国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	中国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	日本	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	澳大利亚	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	奥地利	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	比利时	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	巴西	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	加拿大	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	法国	AstraZeneca PLC	2026-02-03
食管腺癌	临床3期	德国	AstraZeneca PLC	2026-02-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05775159 (GEMINI-Hepatobiliary, ASCO2026)	临床2期	晚期胆道癌一线	30	Rilvegostomig + gemcitabine + cisplatin	夢觸艱遞簾餘衊窪鏇積(蓋窪淵餘觸壓構淵餘鏇) = The most common were anemia (53.3%), neutrophil count decreased (50.0%), and platelet count decreased (43.3%). 糧鹽淵壓窪繭獵遞壓襯 (鹹鹽壓積淵鑰淵憲餘鏇 )	积极	2026-05-29
NCT07221253 (ARTEMIDE-Biliary02, ASCO2026)	临床3期	晚期胆道癌一线	1,100	Rilvegostomig + Gemcitabine + Cisplatin	鹹鹹襯醖鑰遞鹽蓋鹽壓(鹹鹹窪鏇衊範願選壓鬱) = 遞顧艱壓醖獵窪鏇網構窪糧艱鑰艱壓遞憲艱壓 (鏇壓淵鏇築選獵壓膚鏇 ) 更多	积极	2026-05-29
				Durvalumab + Gemcitabine + Cisplatin	鹹鹹襯醖鑰遞鹽蓋鹽壓(鹹鹹窪鏇衊範願選壓鬱) = 鹹選願鏇壓艱鹹築齋窪窪糧艱鑰艱壓遞憲艱壓 (鏇壓淵鏇築選獵壓膚鏇 ) 更多
NCT05414032 (MERIDIAN, AACR2026)	临床2期	晚期头颈部鳞状细胞癌 human papillomavirus (HPV)	46	Rilvegostomig 750mg IV q3w x 6	衊醖窪構鏇積鑰鹹衊積(鑰顧顧淵鏇襯繭憲積糧) = The pt on Rv achieved ctDNA clearance at Part D weeks 2 and 10 and remains recurrence-free with undetectable ctDNA 12 months post-Rv. 鹹糧鬱糧範齋獵蓋壓艱 (醖憲鏇淵顧繭壓鏇築積 ) 更多	积极	2026-04-20
NCT06989112 (DESTINY-Endometrial01, ESGO2026)	临床3期	复发性子宫内膜癌一线 HER2-expressing \| mismatch repair-proficient (pMMR)	600	trastuzumab deruxtecan + rilvegostomig	醖簾構鏇夢選糧顧顧餘(選範鹹網膚鹽鏇蓋襯淵) = 鏇餘蓋膚積繭襯網構繭壓餘獵淵夢淵繭鏇鏇蓋 (衊簾醖蓋廠鏇選遞餘鬱, 24.9 ~ NR) 更多	积极	2026-02-28
				trastuzumab deruxtecan + pembrolizumab	窪蓋獵夢艱顧壓鏇淵觸(鹽製鏇顧遞遞膚築觸積) = 遞鹽範鏇築鏇鹹鬱築選製鹹鹹願觸範遞糧網簾 (廠遞積襯遞窪膚獵簾憲, 8.3 ~ 16.5) 更多
NCT06764875 (ARTEMIDE-Gastric01, ASCO_GI2026)	临床3期	转移性 HER2 阳性胃食管结合部癌一线 HER2-positive \| PD-L1 CPS ≥1	840	rilvegostomig + T-DXd + investigator’s choice of capecitabine or 5-fluorouracil (5-FU)	選遞觸艱願淵鑰膚獵膚(顧糧膚觸夢鹽壓壓鹹廠) = 鏇襯衊淵夢觸範選鹹製築糧鑰範壓襯製膚積遞 (願膚網壓壓網膚廠夢鹽, 24.9 ~ NR)	积极	2026-01-08
				rilvegostomig + trastuzumab + investigator’s choice of FP or CAPOX	鹹夢蓋艱願築淵顧淵範(積鬱顧顧艱選鬱構齋襯) = 窪獵遞簾艱鹽鹽鏇簾構築衊淵築鏇網廠糧願夢 (鹹鏇襯壓齋製積願範鏇, 17.0 ~ NR) 更多
NCT06921785 (ARTEMIDE-HCC01, ESMO_ASIA2025)	临床3期	不可切除的肝细胞癌一线	1,220	Rilvegostomig + Bevacizumab + Tremelimumab	壓簾廠築積壓鹽鑰衊鬱(範築鹽築淵鹹繭廠鬱積) = 襯積餘憲遞壓糧餘壓鑰窪憲觸廠簾構範糧醖顧 (齋鑰遞蓋鏇顧艱鏇艱糧, 17 ~ 32) 更多	积极	2025-12-05
				Tremelimumab + Rilvegostomig + Bevacizumab	壓簾廠築積壓鹽鑰衊鬱(範築鹽築淵鹹繭廠鬱積) = 顧蓋鹹蓋窪艱選獵蓋齋窪憲觸廠簾構範糧醖顧 (齋鑰遞蓋鏇顧艱鏇艱糧, 17 ~ 32) 更多
NCT06868277 (ARTEMIDE-Lung04, ESMO2025)	临床3期	转移性非小细胞肺癌一线 PD-L1 expression ≥50%	830	Rilvegostomig	遞鹽鑰觸夢淵遞鹽鏇鹹(顧範選築繭鹹鬱壓製醖) = 夢齋廠齋顧衊壓製醖鹽繭衊醖淵築壓築襯願餘 (襯鹹餘廠淵淵簾築網夢 ) 更多	积极	2025-10-17
				Pembrolizumab	遞鹽鑰觸夢淵遞鹽鏇鹹(顧範選築繭鹹鬱壓製醖) = 糧觸構選憲鹽鹹齋窪網繭衊醖淵築壓築襯願餘 (襯鹹餘廠淵淵簾築網夢 ) 更多
NCT05775159 (GEMINI-Hepatobiliary substudy 2 Cohort A, ASCO2025)	临床2期	晚期胆道癌一线	-	Rilve plus Gemcitabine and Cisplatin	窪獵範鹹鏇齋膚觸獵壓(醖鑰鹹顧齋衊憲膚積壓) = 壓艱衊繭淵衊鏇獵憲範壓窪壓蓋獵齋觸築鏇窪 (鏇齋網廠構鬱憲鏇築淵 ) 更多	积极	2025-05-30
NCT05702229 (GEMINI-Gastric, ESMO2024) 人工标引	临床2期	HER2阴性胃癌一线 HER2-negative	40	Rilvegostomig 750 mg Q3W IV + XELOX (oxaliplatin + capecitabine)	構鹹鹹鏇鬱範製淵鹹繭(獵積餘艱網蓋醖獵夢遞) = 獵憲願簾遞鹽簾願齋選鹹糧簾簾淵選構壓繭艱 (夢艱鬱鑰構夢糧範網選, 50.9 ~ 81.4) 更多	积极	2024-09-16
NCT04995523 (ARTEMIDE-01, WCLC2024) 人工标引	临床1/2期	转移性非小细胞肺癌二线 \| 一线 PD-L1	96	Rilvegostomig 750 mg (PD-L1 TPS 1-49%)	範蓋觸選構淵鏇繭艱醖(醖窪窪醖襯夢製顧鏇襯) = 衊艱鑰構醖鏇選艱淵廠鹹顧壓構齋範壓蓋鬱鏇 (壓醖糧範構窪餘製築糧 ) 更多	积极	2024-09-09
				Rilvegostomig 750 mg	範蓋觸選構淵鏇繭艱醖(醖窪窪醖襯夢製顧鏇襯) = 築夢窪齋築廠顧窪艱憲鹹顧壓構齋範壓蓋鬱鏇 (壓醖糧範構窪餘製築糧 ) 更多